Multiplex Assay Kit for Salusin Beta (SALb) ,etc. by FLIA (Flow Luminescence Immunoassay) 
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 474.00 US$ 492.00 US$ 520.00 US$ 556.00 US$ 593.00 US$ 648.00 US$ 730.00 US$ 912.00
- Quantity
Overview
Properties
- Product No.LMC026Ra
- Organism SpeciesRattus norvegicus (Rat) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayEndocrinologyCardiovascular biologyNeuro scienceHormone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Salusin Beta (SALb) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Salusin Beta (SALb) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 88-95 | 91 |
| EDTA plasma(n=5) | 84-99 | 90 |
| heparin plasma(n=5) | 85-102 | 92 |
| sodium citrate plasma(n=5) | 78-99 | 83 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Salusin Beta (SALb) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Salusin Beta (SALb) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Salusin Beta (SALb) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 94-102% | 95-103% | 80-92% | 89-96% |
| EDTA plasma(n=5) | 91-104% | 84-103% | 79-104% | 78-101% |
| heparin plasma(n=5) | 80-91% | 85-92% | 80-89% | 94-101% |
| sodium citrate plasma(n=5) | 83-93% | 87-101% | 84-96% | 83-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:SALb) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards,Labeled antigen and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest.A competitive inhibition reaction is launched between biotin labeled analytes of interest and unlabeled analytes of interest (Standards or samples) with the pre-coated antibody specific to analytes of interest. Following a wash to remove any unbound substances, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE) is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer. The MFI developed is reverse proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Serum levels of apelin, salusin-alpha, and salusin-beta in normal pregnancy and preeclampsiaInforma: 14767058.2012.660221
- The bioactive peptides salusins and apelin–36 are produced in human arterial and venous tissues and the changes of their levels during cardiopulmonary bypassPubMed: 22884920
- Presence of adropin, nesfatin-1, apelin-12, ghrelins and salusins peptides in the milk, cheese whey and plasma of dairy cowsScienceDirect: S0196978113000533
- Association of low maternal levels of salusins with gestational diabetes mellitus and with small-for-gestational-age fetuses.PubMed: 23178004
- Serum concentration and kidney expression of salusin-α and salusin-β in rats with metabolic syndrome induced by fructose.PubMed: 23244237
- Salusins, newly identified regulators of hemodynamics and mitogenesis, increase in polycystic ovarian syndrome.PubMed: 22827297
- Concentrations of preptin, salusins and hepcidins in plasma and milk of lactating women with or without gestational diabetes mellitusScienceDirect: S0196978113003100
- Salusin-alpha and -beta expression in heart and aorta with and without metabolic syndrome Com:Source
- Brain, Liver, and Serum Salusin-alpha and-beta Alterations in Sprague-Dawley Rats with or Without Metabolic SyndromePubmed:Pmc4136931
- Superoxide anions involved in sympathoexcitation and pressor effects of salusin-β in paraventricular nucleus in hypertensive ratsPubmed:24304512
- Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population?Pubmed:25245503
- Serum salusin-α and salusin-β levels in patients with psoriasisPubMed: 26055619
- Serum Salusin-β Levels Are Associated With the Presence and Severity of Coronary Artery DiseasePubMed: 25730454
- Serum Salusin-β Levels Are Correlated with Slow Coronary Flow.Pubmed:27227272
- Silencing salusin-β attenuates cardiovascular remodeling and hypertension in spontaneously hypertensive rats.pubmed:28230187
- Salusin-β contributes to oxidative stress and inflammation in diabetic cardiomyopathypubmed:28333148
- Salusin-β Is Involved in Diabetes Mellitus-Induced Endothelial Dysfunction via Degradation of Peroxisome Proliferator-Activated Receptor Gamma10.1155:2017
- Silencing salusin β ameliorates heart failure in aged spontaneously hypertensive rats by ROS-relative MAPK/NF-κB pathways in the paraventricular nucleusPubmed: 30581101
- Increased level of Plasma Salusin-α and Salusin-β in patients with Multiple SclerosisPubmed: 30738876
- Salusin-α levels are negatively correlated with diastolic blood pressure in children with obesityPubmed: 31486354
- Salusin-β mediates tubular cell apoptosis in acute kidney injury: Involvement of the PKC/ROS signaling pathwayPubmed: 31884071
- Salusin-β is superior to salusin-α as a marker for evaluating coronary atherosclerosisPubmed: 32054363
- A TOR2A Gene Product: Salusin-β Contributes to Attenuated Vasodilatation of Spontaneously Hypertensive Rats.Pubmed: 32458319
- Serum level of salusin β as an indicator of metabolic disorders in Acute Lymphoblastic Leucaemia and Wilms Tumour survivors
- Salusin‑β participates in high glucose‑induced HK‑2 cell ferroptosis in a Nrf‑2‑dependent manner34296310